Fig. 7

Synergistic effect of intratumoral ISF35 with anti-CTLA-4 and anti-PD-1 antibody therapy against melanoma in the brain. a Treatment strategy. b Mouse survival. c Cause of death (s.c. or brain tumor). d Representative luminescence images from treated animals. Data are from two pooled independent experiments (n = 7 in each experiment). Survival analysis was performed with the log-rank test. ***P < 0.0005